INVEST IN EVOQ BIO · BIOTECHNOLOGY
EVOQ Bio is a pre-clinical drug development company engineering EVQ-218, a novel antimicrobial candidate targeting pathogens associated with multidrug-resistant lung infections. Peer-reviewed research published in the journal ACS Omega characterizes the precise nanoscale architecture of the platform, while a peer-reviewed study published in the journal Antibiotics demonstrates broad-spectrum antimicrobial activity and no observed resistance over 30 serial passages under conditions where standard-of-care antibiotics showed diminished performance. Supported by $498,000 in awards from the Cystic Fibrosis Foundation, the company has engaged with the FDA through a Pre-IND meeting and is advancing the program toward clinical trials.
This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
